Non-invasive Glucose Monitoring
GWave is the world's first non-invasive glucometer, which offers a disruptive solution utilizing radio frequency (RF) waves to continuously measure glucose levels in the blood.
The revolutionary concept was conceived by GWave’s CTO and Co-founder, Dr. Geri Waintraub, when he accidently spilled a cup of tea on an RF device during routine experimentation for an RF research initiative.
He immediately noticed that the sugar in the tea caused the dramatic reaction on the system’s monitors.
Following the serendipitous spill, Dr. Waintraub began formulating ideas about the enormous applications the technology could have toward helping hundreds of millions of people with diabetes worldwide.
GWave’s technology was developed into a prototype that yielded a successful POC with astonishing results that meet the FDA guidelines.
Utilizes RF Wave technology that monitors glucose levels in the blood continuously and in real-time. User safety is our foremost priority, using significantly less radiation than a smartphone.
GWave’s sensors are developed with propriety AI algorithms that enables GWave to be cost-efficient, compact, and capable of delivering impeccably accurate measurements.
Our device seamlessly connects to Bluetooth and smartphones, creating a painless, straightforward and pleasant user experience.
Users can track their glucose readings as frequently and repeatedly as needed.
The built-in automated alarm feature is a key benefit to ensure proper notification to the user of fluctuation in glucose levels.
Our cloud securely stores all the user’s measurement data, and can deliver important information to caretakers and medical professionals. Our software is safe, secure, and reliable.
Our device’s accuracy is over 95% when compared to an off-theshelf handheld finger-prick device.
With GWave’s innovative technology, glucose is monitored in the blood and not in the interstitial fluid. Monitoring the blood itself yields efficient and incredibly accurate results.
HAGAR Unveils New Clinical Data on Groundbreaking GWave Technology, Closing Round C Funding
HAGAR, the startup behind GWave, a non-invasive continuous glucose monitoring system, successfully secured a $5 million Series C funding round, bringing its total funding to $25 million. The startup recently showcased its latest clinical findings at the 83rd Scientific Sessions of the American Diabetes Association (ADA).